ABBV logo

ABBVIE INC

ABBVNYSE
πŸ† #24 by market capEarnings Feb 3US Equity
$286.20β–² $2.67 (+0.94%)
Market closed Β· at close
πŸ””
Track ABBV
Get earnings, price moves & breaking news on Telegram
Track
24hβ–² 0.9%
7dβ–Ό 3.0%
14dβ–Ό 1.8%
30dβ–² 0.2%
ytdβ–² 25.3%
1yβ–² 21.1%
🏦Market Cap
$505.75B
Large Cap
πŸ“ˆRevenue Growth (YoY)
10.7%
Healthy
πŸ“ŠGross Margin
73.7%
High
πŸ’΅FCF Margin
28.6%
Strong
βš–οΈP/S Ratio
7.6x
Fair
Otter Score
72
Strong

Trading Snapshot

Day Range
$284.88 – $290.23
52-Week Range
$190.75 – $302.93
Volume (shares)
8,755,117
Avg Volume (shares)
β€”
Shares Outstanding
1.77B
Next Earnings
2027-02-03

Fundamentals Snapshot

Annual Revenue
$61.16B
Last Q Revenue
$17.40B
P/E Ratio
48.5
P/S Ratio
7.6x
EPS (TTM)
$5.83
Dividend Yield
2.42%
Dilution (1yr)
+0.1%
ABBV logo

ABBVIE INC

ABBV
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$61.2Bβ–² +8.6% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
70.2%β–² +0.3% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$20.1Bβ–² +119.9% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$17.8Bβ–Ό βˆ’0.1% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
1.77Bβ–² +0.1% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$63.6Bβ–Ό βˆ’$1.3B YoY
StockOtter Β· stockotter.space

About ABBVIE INC

AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal BehΓ§et's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Strong
72/100
Analyst data unavailable.

Latest News & Updates

24/7 Wall StreetΒ·1d ago

$500,000 in AbbVie and Gilead Could Pay More Than $11,000 a Year in Dividends

One drugmaker's earnings look broken on paper, while the other carries negative equity and a mountain of new debt. Both still hand retirees raises every year, so why would anyone trust them with half a million dollars?

The Motley FoolΒ·1d ago

AbbVie (ABBV) Stock Just Got a 5.2% Dividend Increase. Here's How Many Shares You Need to Generate $1,000 a Year.

AbbVie's dividend yield of 2.4% is solid, but more importantly, it's been growing at an impressive clip. The stock isn't cheap, but it warrants consideration for a long-term portfolio.

Fool - Investing NewsΒ·1d ago

Breakfast News: When Tech Wobbles, Dividends Pay

Motley Fool analysts share their favorite dividend stocks as tech stocks wobble.

247 WallstΒ·2d ago

5 High-Yield Healthcare Stocks for a Tax-Free Roth IRA Income Stream

One stock in this five-name healthcare basket costs more in annual tax than the other four combined, and the IRS treats its payout differently from the rest. Find out which one belongs in your Roth first.

The Motley FoolΒ·2d ago

AbbVie vs. Eli Lilly: Which Healthcare Stock Is a Better Buy for 2027?

AbbVie generates significant cash flow from its newer immunology stars, Skyrizi and Rinvoq. Eli Lilly is seeing explosive revenue growth driven by its dominant presence in the metabolic health market.

PRNewsWireΒ·2d ago

AbbVie to Present at the Piper Sandler 38th Annual Healthcare Conference

NORTH CHICAGO, Ill., Nov. 20, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Piper Sandler 38th Annual Healthcare Conference on Wednesday, December 2, 2026.